Journal
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
Volume 21, Issue 16, Pages 2163-2180Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1871520621666210129093116
Keywords
Cancer; carbonic anhydrase; cyclooxygenase-2; dual enzyme inhibitors; Structure-Activity Relationships (SAR); sulfonamide
Categories
Ask authors/readers for more resources
COX-2 selective inhibitors belonging to the sulfonamide class demonstrate inhibitory action against cancer-related hCA isoforms, potentially contributing to their antineoplastic activity. Further exploration is needed regarding the possible use of these compounds in cancer prevention and combination therapy.
Human Carbonic Anhydrase (hCA) and Cyclooxygenase-2 (COX-2) have been known for a long to be chiefly involved in both the pathogenesis and progression of cancer and cancer chemoresistance. Interestingly, there is considerable evidence that the sulfonamide-type COX-2 selective inhibitors (coxibs) demonstrate inhibitory action against the cancer-related hCA isoforms, confirmed by X-ray crystal structures for celecoxib and valdecoxib complexes with the hCA active site. Consequently, the antineoplastic activity of the sulfonamide coxibs may be justified by the contribution of hCA inhibition to such processes in addition to COX-2 inhibition. Accordingly, these compounds' anti-tumoral activity should be further explored for their possible use in cancer prevention and combination therapy; however, few papers deal with this issue. Beginning with a brief description of the main molecular and catalytic features of both enzymes and their roles in tumor physiology, this review covers a survey of the most recent evidence regarding the molecules targeting one or both of hCA and COX-2, besides providing insights into their mechanism of action and efficacy in preventing cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available